Publicacións nas que colabora con FRANCISCO J. DE LA SERNA TORROBA (9)

2010

  1. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome

    Blood, Vol. 115, Núm. 25, pp. 5137-5146

2009

  1. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis

    Haematologica, Vol. 94, Núm. 9, pp. 1242-1249

2008

  1. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

    Blood, Vol. 111, Núm. 7, pp. 3395-3402

2004

  1. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia

    Blood, Vol. 104, Núm. 12, pp. 3490-3493

2001

  1. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

    Journal of Clinical Oncology, Vol. 19, Núm. 5, pp. 1395-1404

2000

  1. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A comparative study of efficacy and toxicity from the Spanish Registry for transplantation in multiple myeloma

    British Journal of Haematology, Vol. 109, Núm. 1, pp. 138-147

  2. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

    British Journal of Haematology, Vol. 109, Núm. 2, pp. 438-446

1998

  1. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry

    Bone Marrow Transplantation, Vol. 21, Núm. 2, pp. 133-140

1997

  1. Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia

    Leukemia and Lymphoma, Vol. 25, Núm. 3-4, pp. 365-372